Hero patient

PNH unmet needs

PNH is associated with a significant clinical and economic burden.1

Left untreated, people living with PNH are at increased risk of life-threatening complications and experience a significant QoL impact with high frequency and severity of daily symptoms.1

They key sources of burden for PNH patients include:1

  • Risk of thrombosis: A burden of disease study in Europe (n=71) reported that 38% of patients had experienced at least one thrombotic event in their lifetime1 2
  • Transfusion risks: The need for blood transfusions is quite common for people with PNH due to the high prevalence of chronic anaemia. Transfusions are associated with a risk of reaction, development of antibodies and iron overload (21% of patients)
  • Severe fatigue: The most common symptom in people living with PNH despite current available treatment options.
  • Economic impact: Both at an individual patient level, due to an impaired ability to work, and at a healthcare system level, given the significant requirements for medical interventions.
  • Risk of thrombosis: A burden of disease study in Europe (n=71) reported that 38% of patients had experienced at least one thrombotic event in their lifetime1 2

Journey to address these unmet medical needs

Video recording from Rare Disease Policy Event, sponsored by Sobi in partnership with EUCOPE and Partnering4PNH in the European Parliament, 1st of March 2023.


References
 

The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life - Panse - 2022 - European Journal of Haematology - Wiley Online Library.” https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13816 (accessed Oct. 31, 2022).
2 M. Griffin, R. Kelly, and A. Pike, “A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?,” https://doi.org/10.1177/2633004020959349, vol. 1, p. 263300402095934, Oct. 2020, doi: 10.1177/2633004020959349.
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France,
Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life - Panse - 2022 - European Journal of Haematology - Wiley Online Library.” https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.13816 (accessed Oct. 31, 2022)

Job code: NP-29567  | Date of preparation: April 2024

Intended for healthcare professional only